Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes (COMET)

Clinical Trial ID NCT01386671

Rank	Title	Journal	Year	PubWeight™‹?›
1	10-year follow-up of intensive glucose control in type 2 diabetes.	N Engl J Med	2008	35.49
2	Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.	Lancet	1998	34.34
3	Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.	JAMA	2010	4.45
4	Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.	Arch Intern Med	2008	3.54
5	Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.	BMJ	2009	2.42
6	Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.	Diabet Med	2005	1.35
7	Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.	Diabet Med	1994	1.03